WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies ...
WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (MURA) (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine ...
WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (MURA) (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine ...